BOSTON - Elicio Therapeutics , Inc. (NASDAQ:ELTX), a clinical-stage biotech company focusing on cancer immunotherapies, has announced a registered direct offering priced at-the-market under Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback